$27.79
+0.86 (+3.19%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NRIX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional
Held by 10 tracked-famous managers (CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., AQR CAPITAL MANAGEMENT LLC, Qube Research & Technologies Ltd, Man Group plc, +5 more) · FINRA short interest 18.0 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 3 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesNCT07520006Number of participants with treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: NX-5948, venetoclax, rituximab, obinutuzumab | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 150 | May 2033 | ≤ 2,476 d | 2026-04-13 |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNCT07516093Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)Randomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: NX-5948, Pirtobrutinib | B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 620 | Oct 2029 | ≤ 1,168 d | 2026-04-08 |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)NCT07221500Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC)Open-label · Treatment | Phase 2 | Recruiting | Drug: NX-5948 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 100 | Jan 2028 | ≤ 529 d | 2026-08-19 |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNCT05131022Number of participants with protocol specified dose-limiting toxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: NX-5948 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) | 572 | Jan 2027 | ≤ 164 d | 2026-07-02 |
| A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: NX-1607, Paclitaxel | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 345 | 2026-08-31 | in 11 d | 2025-09-09 |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesNCT04830137Number of Participants with Protocol Specified Dose-Limiting ToxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: NX-2127 | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL) | 248 | May 2026 | — | 2026-03-20 |
| A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy VolunteersNCT06717269Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine, NX-5948 | Healthy Volunteer | 223 | 2026-05-01actual | — | 2026-07-28 |
| Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948NCT06691828Characterize Area Under the Curve (AUC0-inf), Half-life (T1/2) after IV dosing of NX-5948Open-label · Treatment | Phase 1 | Completed | Drug: NX-5948 | Healthy Volunteer | 8 | 2024-11-28actual | — | 2025-03-12 |
| A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult SubjectsNCT06593457Part 1 Food Effect: AUC0-t for NX-5948 administered under fed and fasted conditionsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: IP, Matching Placebo | Healthy Volunteers | 32 | 2024-10-29actual | — | 2025-03-14 |
| A Study of DeTIL-0255 in Adults With Advanced MalignanciesNCT05107739Incidence of treatment emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision | Biological: Drug Product De-TIL-0255 | Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer | 5 | 2023-05-09actual | — | 2024-05-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19